Table 4.

Adverse Events of Grade ≥3 During the Observation Period.

	All, n = 94		Child-Pugh class A, n = 62		Child-Pugh class B, n = 32
	TACL-ECF, n = 49	Sorafenib group, n = 45	TACL-ECF, n = 33	Sorafenib group, n = 29	TACL-ECF, n = 16	Sorafenib group, n = 16
Nausea/vomiting	1 (2.0%)	1 (2.2%)	0 (0%)	0 (0%)	1 (6.3%)	1 (6.3%)
Fatigue	1 (2.0%)	1 (2.2%)	0 (0%)	1 (3.4%)	1 (6.3%)	0 (0%)
Hand-foot syndrome	0 (0%)	4 (8.9%)	0 (0%)	3 (10.3%)	0 (0%)	1 (6.3%)
Elevated aspartate aminotransferase	3 (6.1%)	6 (13.3%)	1 (3.0%)	2 (6.9%)	2 (12.5%)	4 (25.0%)
Bone marrow suppression	1 (2.0%)	0 (0%)	1 (3.0%)	0 (0%)	0 (0%)	0 (0%)
Hepatic encephalopathy	0 (0%)	1 (2.2%)	0 (0%)	0 (0%)	0 (0%)	1 (6.3%)
Variceal bleed	0 (0%)	2 (4.4%)	0 (0%)	1 (3.4%)	0 (0%)	1 (6.3%)
Pulmonary thromboembolism	0 (0%)	1 (2.2%)	0 (0%)	1 (3.4%)	0 (0%)	0 (0%)